All Posts

ESMO 2026 SNEAK PEEK

█ For kidney cancer, ESMO 2026 has one of its most concentrated programmes in years. Nearly all of the practice-relevant renal data come on a single day, Sunday, October 25. The morning Proffered Paper session puts both phase 3 belzutifan readouts, a…

Articles by KidNEYCAnCeR 2 days ago

29Views 0Comments

Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC

#Equal Contributions as Senior/Supervising Authors ϮAddress Correspondence: Abhishek A. Chakraborty, PhD Department of Cancer Sciences, Cleveland Clinic, Cleveland OH E-mail: chakraa@ccf.org Conflict of Interest: The authors declare no conflict of interest with this study. INTRODUCTION Clinical outcomes for patients…

37Views 0Comments

Stereotactic Body Radiotherapy for Primary Renal Tumors: Technological Evolution, Current Evidence and Practical Recommendations

1. Introduction and Background Renal cell carcinoma (RCC) is frequently detected incidentally on imaging tests performed for other reasons, and its incidence continues to increase, particularly in the elderly (1). Although surgical resection of the tumor remains the treatment of choice…

36Views 0Comments

The Adjuvant Reckoning: Belzutifan,Toxicity, and the Next Phase of RCC Care

Dear Colleagues, This has been an unusually productive stretch for renal cell carcinoma (RCC) research, and the Third Quarter 2026 issue of Kidney Cancer Journal reflects that momentum. Between the follow-through from ASCO's Genitourinary Cancers Symposium earlier this year and the full…

Articles by KidNEYCAnCeR July 1, 2026

691Views 0Comments

EXPERT COMMENTARY – ASCO26

Perspectives synthesized from ASCO 2026 presenter and discussant sessions and post-meeting expert commentary. Prepared for educational purposes by the Kidney Cancer Journal editorial team. Toni K. Choueiri, MD, FASCO. Dana-Farber Cancer Institute, Boston, MA. Presenter — LITESPARK-022 and KEYNOTE-564 ctDNA Analysis…

Latest Updates by KidNEYCAnCeR June 17, 2026

605Views 0Comments

Management of Carcinoid Tumor within a Horseshoe Kidney

Andrea Lopez Sanmiguel1, Dilara Akbulut1, Jeff Chen1, Yash S. Khandwala1, Paul Russo1† Affiliations: 1 Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY Abstract Horseshoe kidney is the most common renal fusion…

Articles by KidNEYCAnCeR June 17, 2026

3084Views 0Comments

ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights

doi.org/10.52733/ASCO26Summary Thomas E. Hutson, DO, PharmD, FACP Editor-in-Chief, Kidney Cancer Journal A Summary Report for the Global Oncology Community Chicago, Illinois | May 29 – June 2, 2026 | Kidney Cancer Journal, Volume 24…

2026 ASCO Latest Updates by KidNEYCAnCeR June 17, 2026

3054Views 0Comments

The Architecture of a Cure: Where Renal Cell Carcinoma Research Stands in 2026

Thomas E. Hutson, DO, PharmD, FACP EDITORIAL NOTE | Editor-in-Chief, Kidney Cancer Journal There is a particular kind of optimism that belongs only to a field in the midst of genuine transformation…

Articles Latest Updates by KidNEYCAnCeR June 15, 2026

3761Views 0Comments

Most Clinically Significant Kidney Cancer Presentations from ASCO 2026

Selected by the Editor-in-Chief | Kidney Cancer Journal, Volume 24(2) Primary data drawn from ASCO 2026 presentations, JCO supplement abstracts, press releases, and peer-reviewed commentary. Abstract 1 — LBA418 LITESPARK-022: Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Clear…

930Views 0Comments

Journal Club

Significant Recent Publications in Kidney Cancer Curated by the Editorial Team, Kidney Cancer Journal | Volume 24(2) Includes clinical trials and randomized controlled trials published within the past 10 weeks in high-impact peer-reviewed journals. █ CheckMate 9ER Final Analysis:…

All Posts

ESMO 2026 SNEAK PEEK

Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC

Stereotactic Body Radiotherapy for Primary Renal Tumors: Technological Evolution, Current Evidence and Practical Recommendations

The Adjuvant Reckoning: Belzutifan,Toxicity, and the Next Phase of RCC Care

EXPERT COMMENTARY – ASCO26

Management of Carcinoid Tumor within a Horseshoe Kidney

ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights

The Architecture of a Cure: Where Renal Cell Carcinoma Research Stands in 2026

Most Clinically Significant Kidney Cancer Presentations from ASCO 2026

Journal Club

About Us

Contents

Follow Us

Guidelines

Patient Resources